DES/RHU/PGA/db September 20, 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1647

Applicants:

Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks and Lijun Wu

Application No.:

09/940,063

Group Art Unit:

1647

Filed:

August 27, 2001

Examiner:

Jon M. Lockard, Ph.D.

PATENT APPLICATION

DOCKET NO.: 1855.1070-004

Confirmation No.:

3846

Title:

ANTIBODIES AND LIGANDS FOR "BONZO" CHEMOKINE

RECEPTOR (As Amended)



09/23/2005 MWDLDGE1 00000040 080380

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

Date Signature
Tennifer Towner

09940063 Typed or printed name of person

01 FC:1806

180.00 DA

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

The PTO did not receive the following listed Item(s) hock # 180

Sir:	listed Item(s) hock (\$1.80)
This Ir	information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[ ]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[X]	under 37 CFR 1.97(c) together with either:  [ ] a Statement under 37 CFR 1.97(e), as checked below, or
	[X] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[ ]	under 37 CFR 1.97(d) together with:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application file.

(Filed after payment of issue fee)

Statem	ent Unc	der 37 C	<u>FR 1.97(e)</u>			
]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
Statem	nent Und	der 37 C	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000			
[ ]	commitwas no	unicatio ot receiv	nformation contained in the Information Disclosure Statement was cited in a n from a foreign patent office in a counterpart application and this communication ed by any individual designated in § 1.56(c) more than thirty days prior to the formation Disclosure Statement.			
[X]	Enclos	sed here	with is form PTO-1449:			
	[X] Copies of the cited references, AX6-AZ6 and AR7, are enclosed.					
		[X]	Copies of issued U.S. patents and published U.S. applications (i.e., AK) are not required and are not being provided.			
	[]	Applic	s of the cited references are enclosed except those entered in prior application, U.S. eation No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]			
	[ ]	The lis	sted references were cited in the enclosed International Search Report in a rpart foreign application.			
	[ ]	The "c under	oncise explanation" requirement (non-English references) for reference(s) [ ] 37 CFR 1.98(a)(3) is satisfied by:			
		[ ]	the explanation provided on the attached sheet.			
		[ ]	the explanation provided in the Specification.			
		[ ]	submission of the enclosed International Search Report.			
		[ ]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.			
		[ ]	the enclosed English language abstract.			

[]	Applic	ant requests that the following n	on-published pending applic	ations be considered:
Examiner's Initials				
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		Examiner	Date	_
	[]	A copy of each above-cited app any application filed on or after Image File Wrapper (IFW) syst	r June 30, 2003, which has b	een scanned into the PTO's
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.		nt claims, is enclosed, except ], to which priority under
The Ex	kaminer	is requested to return a copy of re considered with the next offic	the above list of pending appear communication.	plications indicating which
It is re	quested	that the information disclosed h	nerein be made of record in the	nis application.
Metho	d of pay	yment:		
[X]		ck for the fee noted above is enc panying Reply. A copy of this S		cluded in the check with the
[ ]	Please enclos	charge Deposit Account 08-038 ed.	30 in the amount of \$[	. A copy of this Statement is
[X]	Please	charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.
		I	Respectfully submitted,	
		I	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
		I	Paul G. Alloway Registration No.: L0014 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	<i>y</i>

Concord, MA 01742-9133
Dated: 20, 2005

PTO-1449 REPRODUCED			PPLICATION NO. 9/940,063	
O INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Michael J. Briskin		FILING DATE August 27, 2001	
SEP 2 2 7 (Use several sheets if necessary)	EXAMINER Jon M. Lockard, Ph.D.	CONFI 3846	RMATION NO.	GROUP 1647

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AK	2003-0165995-A1	09/04/2003	Michael J. Briskin, et al.

	F	OREIGN PATENT DO	DCUMENTS			
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO		
					-	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
Yoshimura, A., et al., "Negative Regulation of Cytokine Signaling Influences Inflammation," Curr. Opin. Immunol., 15:704-708 (2003).						
AY6	Choy, E. H. S. and Panayi, G. S., "Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis," N. Engl. J. Med., 344(12):907-916 (2001).					
Doranz, B. J., et al., "Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions," J. Virol., 73(4):2752-2761 (1999).						
Hesselgesser, J., et al., "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor," J. Biol. Chem., 273(25):15687-15692 (1998).				ists of		

EXAMINER	DATE CONSIDERED